Format

Send to

Choose Destination
Br J Cancer. 2011 Apr 12;104(8):1241-5. doi: 10.1038/bjc.2011.62. Epub 2011 Mar 1.

The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer.

Author information

1
Novartis Oncology Translational Research, Novartis Pharmaceuticals, 250 Massachusetts Avenue, Cambridge, MA 02139, USA.

Abstract

The epithelial growth factor receptor (EGFR) family of receptor tyrosine kinases has been reported to have an active role in a number of malignancies. Amplifications and overexpression of various EGFR family members, including EGFR, Her2, and ErbB3, have been reported in epithelial ovarian cancer. Although anti-EGFR-targeted therapy has shown limited clinical activity in ovarian cancer to date, a recent report suggests that activation of ErbB3, one of the members of the EGFR family, may support the growth and proliferation of ovarian cancer cells and that ErbB3 may therefore serve as a potential therapeutic target in this disease. Here, we review the EGFR family and the clinical experience with anti-EGFR family member-directed therapies in ovarian cancer to date.

PMID:
21364581
PMCID:
PMC3078592
DOI:
10.1038/bjc.2011.62
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center